Potential of the SPY intraoperative perfusion assessment system to reduce ischemic complications in immediate postmastectomy breast reconstruction

Table 1 Baseline characteristics of subjects

	Pre-SPY	Post-SPY	P-value*
N	52	39
Age, mean (SD)	52 (7.9)	51 (8.6)	0.5666
Any smoking, N (%)	13 (25.5)**	14 (35.9)	0.3550
Comorbidities present, total, N (%)	40 (78.4)**	24 (61.5)	0.1020
Diabetes, N (%)		3 (7.7%)	1.000
Obesity, N (%)	5 (9.6%)	2 (5.1%)	1.000
Obesity, N (%)	2 (3.8%)
Tumor status, N (%)
T1	21 (40.4)	10 (25.6)	NS^†
≥T2	26 (50.0)	24 (46.2)
N0	27 (51.9)	19 (48.7)
≥N1	21 (40.4)	15 (28.8)
M0	42 (80.8)	32 (82.1)
M1	5 (9.6)	2 (5.1)
DCIS	5 (9.6)	2 (5.1)
Other	1 (1.9)	3 (7.7)
Therapy
Any chemotherapy, N (%)	40 (76.9)	25 (64)	NS^‡
Any hormonal therapy, N (%)	29 (55.8)	18 (46.1)
Any radiation, N (%)	27 (51.9)	17 (43.6)
No therapy, N (%)	4 (7.7)	5 (12.8)

* Unpaired two-tailed t-test.
** Data missing for one subject.
^† No significant interaction by group and tumor status: T1 vs. >T1, N0 vs. >N0, or M0 vs. M1, Fisher’s exact test.
^‡ No significant interaction by group and each therapy vs. absence of each therapy, Fisher’s exact test.
DCIS: ductal carcinoma in situ.
NS: Not significant at P < 0.05.
Note: identified comorbidities included hypertension, diabetes, obesity, asthma, hyperlipidemia, thyroid disease, gastroesophageal reflux disease, osteoporosis, irritable bowel syndrome, thyroid disease, arthritis, endometriosis, chronic bronchitis, sinusitis, hepatitis B, deep vein thrombosis, rheumatic fever, lupus, obstructive sleep apnea, sickle cell disease, anxiety, and depression.

ISSN: 1750-1164